Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00889954 · ClinicalTrials.gov registry record · Phase 1
Her2 and TGFBeta Cytotoxic T Cells in Treatment of Her2 Positive Malignancy
A Phase 1 study, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT00889954 is a Phase 1 study that has completed, run by Baylor College of Medicine. The registered enrollment target is 20 participants.
The verdict
NCT00889954, a Phase 1 study, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
Patients have advanced stage cancer. This study is a gene transfer research study using special immune cells. The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancers. This research study combines two different ways of fighting cancer: antibodies and T cells. Investigators hope that both will work better together. Antibodies are proteins that protect the body from diseases caused from infectious diseases and possibly cancer. T cells, also called T lymphocytes, are special infection-fighting blood cells that can kill other cells, including tumor cells or cells that are infected with germs. Both antibodies and T cells have been used to treat patients with cancers: they both have shown promise, but have not been strong enough to cure most patients. T lymphocytes can kill tumor cells but there are normally not enough of them or they are not able to kill all the tumor cells. We have done research in which we have grown "extra" T lymphocytes. We have added genes to those T lymphocytes to help them to recognize tumor cells. Although the results have been promising, we are still doing more research in this area. Antibodies usually circulate in blood and are secreted by other cells of the immune system in response to the presence of germs or abnormal cells in the body. The antibody used in this study is called anti-HER2 (Human Epidermal Growth Factor Receptor 2). This antibody sticks to HER2-positive cancer cells because of a substance on the outside of these cells called HER2.
Interventions
- BIOLOGICAL TGFBeta resistant HER2/EBV-CTLs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2009-05 |
| Est. Completion | 2018-01-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00889954
The ClinicalTrials.gov registry entry for NCT00889954 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TGFBeta resistant HER2/EBV-CTLs is the first listed.
NCT00889954 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00889954 about?
NCT00889954 is a clinical study titled "Her2 and TGFBeta Cytotoxic T Cells in Treatment of Her2 Positive Malignancy". Patients have advanced stage cancer. This study is a gene transfer research study using special immune cells. The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancers. This research study combines two different ways of fighting cancer: antibodi...
What is the current status of trial NCT00889954?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2009-05. Estimated completion is 2018-01-21.
What interventions are being tested in trial NCT00889954?
The interventions under investigation include: TGFBeta resistant HER2/EBV-CTLs (BIOLOGICAL).
Who is sponsoring clinical trial NCT00889954?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.